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We compared the amount of serum Epstein-Barr virus DNA (EBV-
DNA) detected in patients with nasopharyngeal carcinoma (NPC)
in a high-incidence area, represented by Taiwan, and a low-inci-
dence area, represented by Japan, using real-time quantitative
PCR. The median serum EBV-DNA value in 41 Japanese NPC cases
was 5450 copies/ml, and that in in 23 Taiwanese cases was 2125
copies/ml. The median serum EBV-DNA value in all 64 NPC cases
was significantly higher than in control groups. Using receiver-
operating-characteristic (ROC) curves, the sensitivity and specific-
ity of EBV-DNA quantification were determined (cut-off point,
6.87 copies/ml; sensitivity, 0.855; specificity, 0.885) and compared
with those of EBV-viral-capsid-antigen (VCA) titers; the results
showed that EBV-DNA was a more sensitive and specific parame-
ter than EBV-VCA titer. Then, we analyzed 19 NPC patients in
whom recurrence developed (11 Japanese and 8 Taiwanese), and
26 NPC patients in continuous remission. Although there was no
significant difference in EBV-DNA values between Japanese and
Taiwanese patients, the value was significantly higher in the 19
patients with recurrence than in those in remission. ROC analysis
again revealed a higher diagnostic value of EBV-DNA than EBV-
VCA. These results suggest EBV-DNA is a more reliable tumor
marker than EBV-VCA in both high-incidence and low-incidence
areas of NPC. (Cancer Sci 2004; 95: 508–513)
he restricted geographic and ethnic distribution of endemic
nasopharyngeal carcinoma (NPC) is one of its most strik-
ing epidemiologic characteristics. In Southern China, where it
is the third most common form of malignancy amongst males,
incidence rates are between 15 and 50 per 100,000.1) In Taiwan,
which is also considered a high-incidence area, the incidence
rate was reported to be 8.3/100,000 (male) and 3.5/100,000
(female).2, 3) In Japan, the incidence rate was reported to be be-
tween 0.5 and 1 per 100,000, similar to those in North China
and North America, which are both non-endemic or low-inci-
dence areas.4–6)
Recently, cell-free Epstein-Barr virus DNA (EBV-DNA) has
been detected in the plasma and serum of patients with NPC
with the use of real-time quantitative PCR (RQ-PCR).7–11)
Plasma/serum cell-free EBV-DNA has been shown to be mea-
surable in the majority of NPC patients at the time of diagnosis,
and appears to have prognostic significance. To our knowledge,
these studies were conducted in an endemic area, represented
by Hong Kong, while no study in a non-endemic area has been
reported. In the present study, we compared by RQ-PCR the
amount of serum EBV-DNA of NPC patients in a high-inci-
dence area, represented by Taiwan, and a low-incidence area,
represented by Japan. There have been some reports on the di-
agnostic value of serum EBV-DNA compared with EBV-VCA/
EA Ig titers.12) However, these studies used an arbitrary cut-off
and therefore were not statistically meaningful. For this report
we used a different approach made possible by use of receiver-
operating-characteristic (ROC) curve analysis15, 16) for thorough
comparison of the sensitivity and specificity of serum EBV-
DNA with EBV antibody titers. We also compared the results
in patients with recurrence or in remission in both Japan and
Taiwan.
Materials and Methods
Patients. Forty-one Japanese patients with histologically con-
firmed NPC under the care of the Department of Otolaryngol-
ogy at Kanazawa University and the Central Hospital of
Toyama Prefecture and 23 Taiwanese NPC patients at the Na-
tional Taiwan University were recruited prior to initial therapy.
Patients’ characteristics are shown in Table 1A. All patients
were investigated with endoscopy and computed tomography of
the nasopharynx and neck. No patients had clinical evidence of
distant metastasis on presentation. Staging of all patients was
done according to the American Joint Committee on Cancer/
International Union Against Cancer Stage Classification.13)
All patients had radiotherapy to the local and loco-regional
lesion with or without cisplatin-based chemotherapy. After ini-
tial therapy, the patients were assessed by endoscopic examina-
tion of the nasopharynx and clinical examination every 4–12
weeks. If patients developed symptoms indicative of local re-
currence or metastasis, this development was confirmed by
nasopharyngeal biopsy and imaging.
For controls, sera from 12 patients with non-Hodgkin’s lym-
phoma (NHL), 33 patients with head and neck squamous cell
carcinoma (HNSCC), and 20 healthy individuals were investi-
gated.
In addition, sera from 19 NPC patients who had an initial
disease-free period, but subsequent tumor recurrence, were as-
sayed for EBV-DNA; 11 were Japanese and 8 were Taiwanese.
Patients’ characteristics are shown in Table 1B. As controls, 26
NPC patients who had remained in continuous clinical remis-
sion, all of whom were Japanese, were recruited. Blood sam-
ples were taken immediately prior to therapy and at multiple
occasions after initial therapy. Serum Ig titers were measured
routinely. The EBV-DNA was measured from the serum ob-
tained for the routine diagnostic examination. For the recent
samples, written permission in accordance with the ethical stan-
dards of the Ethical Committee of Kanazawa University was
obtained. However, older samples stocked in our laboratory
were used without such permission, because we were examin-
ing only viral, not human, DNA.
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stored at –80°C until further processing. DNA was extracted
using a QIAamp Blood kit (Qiagen, Hilden, Germany) using
the manufacturer’s protocol. Serum samples (100–200 µl) were
used for DNA extraction after addition of 10 µg of poly(A)
(Roche Diagnostics, Basel, Switzerland) as a carrier RNA. A
volume of 50 µl of the final eluate was used.
Real-time quantitative EBV-DNA PCR. The serum EBV-DNA
concentration was measured by means of RQ-PCR of the
BALF5 gene, which encodes the viral DNA polymerase, as re-
ported previously,14) with some modifications. Ten microliters
of extracted serum DNA was used for this assay. As a positive
control, a plasmid that contained the BALF5 gene was con-
structed from pGEM-T vector (Promega, Madison, WI) and
termed pGEM-BALF5. A standard graph of the CT values ob-
tained from serially diluted pGEM-BALF5 (from 10 to 106)
was constructed. Each sample was tested in duplicate, and ev-
ery analysis was tested with negative water blanks and carrier
RNA.
Immunofluorescence assay. Indirect and anticomplement im-
munofluorescence (IF) assays were carried out with Nippon
Kayaku VCA slides and kits (Nippon Kayaku, Tokyo) for the
detection of IgG and IgA antibodies to VCA according to the
manufacturer’s instructions. The serum samples were serially
diluted (1:2), with final dilutions ranging from 1:10 to
1:10,240. The concentration of the antibodies was expressed as
a titer, with the endpoint corresponding to the last dilution that
clearly showed fluorescence. If serum diluted 1:10 showed no
fluorescence, that titer was expressed as 0.
Statistical analysis. Dr. SPSS II J for Windows statistical soft-
ware (SPSS, Inc., Chicago, IL) was used for the data analysis.
The Mann-Whitney test, the Kruskal-Wallis test, or the Mann-
Whitney U test with Bonferroni adjustment was used for com-
parison of the copy numbers of EBV DNA and patient charac-
teristics in each group. Sensitivity and specificity of the data
were assessed by means of the ROC curve method. The differ-
ences between the two means were analyzed according to the
method previously established.15, 16) P values of <0.05 were
considered to be statistically significant.
Results
Serum EBV-DNA levels of Japanese and Taiwanese NPC cases. The
serum EBV-DNA levels of both Japanese and Taiwanese NPC
cases were quantitated by the RQ-PCR method. There was no
significant difference between Japanese and Taiwanese cases in
terms of distribution with respect to gender, age, TNM classifi-
cation, stage, and histology (WHO type), as shown in Table 1A.
Moreover, there was no significant difference between the
EBV-DNA levels in Japanese NPC cases (median, 5450
copies/ml; range, 0–2,347,650 copies/ml) and Taiwanese NPC
cases (median, 2125 copies/ml; range, 0–6,485,925 copies/
ml), as shown Fig. 1A.
Quantitative analysis of serum from NPC and other diseases. To
evaluate the significance of EBV-DNA elevation in patients
with NPC, EBV-DNA was also quantitated in 20 healthy indi-
viduals, 12 NHL patients, and 33 HNSCC patients. The median
EBV-DNA concentration in all 64 NPC patients (41 Japanese
and 23 Taiwanese NPC patients) was 3625 copies/ml (range 0–
6,485,925 copies/ml), which was significantly higher than that
of healthy individuals (0 copies/ml, range 0–372 copies/ml),
NHL patients (0 copies/ml, range 0–26,453 copies/ml), and
HNSCC patients (0 copies/ml, range 0–4786 copies/ml)
(P<0.001) (Fig. 1B). These results suggest that the EBV-DNA
concentration was significantly increased in the serum of pa-
tients with NPC as compared with healthy individuals, and pa-
tients with NHL and HNSCC.
IgG and IgA VCA titers in NPC and other diseases. Elevation of
serum IgG/VCA and IgA/VCA antibodies is a common feature
in patients with NPC. Thus, serum IgG/VCA and IgA/VCA ti-
ters were also examined in healthy individuals, and patients
with NHL and HNSCC. The values of median IgG/VCA titer
were 1:640 (range 0–1:10,240) in NPC, 1:160 (range 1:40–
1:320) in healthy individuals, 1:160 (range 1:40–1:10,240) in
NHL, and 1:160 (range 1:40–1:5120) in HNSCC. The IgG/
VCA titer in NPC was significantly higher than in healthy indi-
viduals and in patients with HNSCC (P=0.005, P=0.01, re-
spectively). However, there was no significant difference
between NPC and NHL (Fig. 1C).
The values of median IgA/VCA titer were 1:20 (range 0–




A. Prior to therapy.
Total patients 41 22
Male/Female 33/8 15/7 NS
Age (mean yr; range) 58 (20–90) 50 (33–79) NS




















Total patients 11 8
Male/Female 7/4 6/2 NS
Age (mean yr; range) 52 (20–68) 55 (29–65) NS



















The values in this table show the number of patients. P values are
from comparisons between the two groups. Tumor classification,
node classification, and overall stage were based on the International
Union Against Cancer (UICC) classification. No patients had distant
metastasis detected. Histological types were classified according to
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00308.fm  Page 510  Friday, May 28, 2004  9:53 AM1:640) in NPC, 0 (range 0–1:20) in healthy individuals, 1:10
(range 0–1:80) in NHL, and 0 (range 0–1:320) in HNSCC. The
IgA/VCA titer in NPC was significantly higher than in healthy
individuals or HNSCC (P=0.017, P=0.044, respectively).
However, no significant difference was found between NPC

























































































Fig. 1. A. Comparison of serum cell-free EBV-
DNA in Japanese and Taiwanese NPC patients.
The categories are on the X-axis. The Y-axis de-
notes the concentration of cell-free EBV-DNA
(copies of EBV-DNA/ml of serum, common loga-
rithmic scale) detected by the PCR system di-
rected at the BALF5 region. The lines inside the
boxes denote the medians. The boxes mark the
interval between the 25th and 75th percentiles.
The open circles mark the data points outside
the 10th and 90th percentiles. NS: not signifi-
cant. B. Comparison of serum cell-free EBV-DNA
in NPC, NHL, HNSCC, and healthy controls. The
categories are on the X-axis. The Y-axis denotes
the concentration of cell-free EBV-DNA. C. Com-
parison of titers of IgG antibodies to VCA in
NPC, NHL, HNSCC, and healthy controls. The cat-
egories are on the X-axis. The Y-axis denotes the
IgG antibody to VCA titer. D. Comparison of ti-
ters of IgA antibodies to VCA in NPC, NHL,
HNSCC, and healthy controls. The categories are
on the X-axis. The Y-axis denotes the IgG anti-



















































































Fig. 2. A. Comparison of serum cell-free EBV-
DNA in Japanese and Taiwanese NPC patients
with recurrence. The categories are on the X-
axis. The Y-axis denotes the concentration of
cell-free EBV-DNA (copies of EBV-DNA/ml of se-
rum, common logarithmic scale). B. Comparison
of serum cell-free EBV-DNA in NPC patients who
had recurrence and in those who remained in
continuous clinical remission. The categories are
on the X-axis. The Y-axis denotes the concentra-
tion of cell-free EBV-DNA (copies of EBV-DNA/
ml of serum, common logarithmic scale). C.
Comparison of IgG/VCA antibody titers in NPC
patients who had recurrence and in those who
remained in continuous clinical remission. NS:
not significant. D. Comparison of IgA/VCA anti-
body titers in NPC patients who had recurrence
and in those who remained in continuous clini-
cal remission.510 Kondo et al.
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remission. To determine the diagnostic value of EBV-DNA,
VCA/IgG, and VCA/IgA for tumor recurrence, these factors
were again quantitated in 19 NPC patients in whom there was
tumor recurrence (11 Japanese and 8 Taiwanese) and also in 26
in continuous clinical remission (all Japanese). As shown in Ta-
ble 1B, there was no significant difference between Japanese
and Taiwanese recurrent cases in terms of distribution with re-
spect to gender, age, stage, and histology (WHO type). More-
over, there was no significant difference between the EBV-
DNA levels in Japanese recurrent cases (median, 2754 copies/
ml; range, 0–1,621,810 copies/ml) and Taiwanese recurrent
cases (median, 6073 copies/ml; range, 0–47,533 copies/ml) as
shown in Fig. 2A.
In the 19 recurrent cases, the median EBV-DNA concentra-
tion at recurrence was 2754 copies/ml (range 0–1,621,810
copies/ml), whereas that in the cases in remission was 0
copies/ml (range 0–7943 copies/ml). The elevation of the se-
rum EBV-DNA concentration in the recurrence group was sta-
tistically significant (P<0.001, Fig. 2B). The median IgG/VCA
titer was 1:640 (range 1:160–1:5120) in the recurrence group
and 1:320 (range 1:20–1:2560) in the group in remission. The
median IgA/VCA titer was 1:20 (range 1:10–1:640) in recur-
rence and 1:10 (range 0–1:320) in cases in remission. The ele-
vations of both IgG/VCA and IgA/VCA titers in the
recurrence group were not significant (P=0.114 and 0.142, re-
spectively) (Fig. 2, C and D).
Diagnostic value of EBV-DNA, IgG/VCA, and IgA/VCA analyzed by
ROC curves prior to therapy. To determine the diagnostic value of
EBV-DNA levels versus IgG/VCA and IgA/VCA titers by
ROC curve analysis, the data from 64 NPC patients prior to ini-
tial therapy were analyzed together with the data from 33
HNSCC patients and 20 healthy individuals as negative con-
trols.
This analysis demonstrated the diagnostic values of the three
assays compared with that of the eye examination, which is the
“gold standard.”15, 16) The areas under the ROC curves were sig-
nificantly larger than the area expected by chance alone for all
three diagnostic tools (P<0.001, Fig. 3A, Table 2A). The diag-
nostic optimal cut-off point determined by this analysis was
6.87 copies/ml for EBV-DNA, 1:640 for IgG/VCA, and 1:20
for IgA/VCA. The sensitivity and specificity of EBV-DNA
quantification obtained by this cut-off point were 0.855 and
0.885, respectively. The sensitivity and specificity of IgG/VCA
with the optimal cut-off point were 0.590 and 0.897, and those
of IgA/VCA were 0.597 and 0.897, respectively. Statistical
analysis of the area under the ROC curves revealed that the
area for serum EBV-DNA was significantly larger than the area
for IgG/VCA or IgA/VCA (P=0.008, P=0.011, respectively).
These results suggest that EBV-DNA quantification is a more
sensitive and specific tumor marker for the diagnosis of NPC
than IgG/VCA or IgA/VCA titers.
Diagnostic value of EBV-DNA, IgG/VCA, and IgA/VCA analyzed by
ROC curves at recurrence. By ROC curve analysis, we determined
the diagnostic value of EBV-DNA levels and IgG/VCA and
IgA/VCA titers at tumor recurrence. The 19 NPC patients who
had tumor recurrence served as the positive subjects, and the 26
who were in continuous complete remission were used as the
negative subjects.
The areas under the ROC curves were significantly larger
than the area expected by chance alone for EBV-DNA quantifi-
cation (P<0.001, Fig. 3B, Table 2A). For IgG/VCA and IgA/
VCA titers, however, there were no significant differences from
the area expected by chance alone, which means that their diag-
nostic value was poor. The diagnostic optimal cut-off point de-
termined by this analysis was 60.3 copies/ml for EBV-DNA.
The sensitivity and specificity of EBV-DNA quantification ob-
tained by this cut-off point were 0.909 and 0.926, respectively.
However, we were not able to determine the cut-off points for
VCA-titers, because they did not have high diagnostic value.
Statistical analysis of the area under the ROC curves revealed
that the area for serum EBV-DNA was significantly larger than
the area for either IgG/VCA or IgA/VCA (P=0.004; and
P<0.001, respectively, Table 2B). These results suggest that
EBV-DNA is a more sensitive and specific tumor marker for
the diagnosis of NPC than IgG/VCA or IgA/VCA, even at tu-
mor recurrence.
Discussion
The recent demonstration of circulating EBV-DNA in plasma
or serum of NPC patients has opened up new possibilities for
detecting and monitoring NPC in endemic areas such as South
China, and also high-incidence area such as Taiwan and else-
where in Southeast Asia.7–11, 12, 17, 18) In the first part of this
study, we explored serum EBV-DNA levels in NPC patients in
a low-incidence area, Japan. The results showed that the
amount of serum EBV-DNA in Japanese NPC patients was in-
creased similarly to that in Taiwanese who showed a statisti-
cally similar distribution of clinical background. Moreover,
there was no significant difference in the EBV-DNA concentra-
tion between the two areas, suggesting that quantification of se-
rum EBV-DNA is useful as a screening method for NPC in
low-incidence as well as high-incidence areas.
In addition to HNSCC and healthy individuals, the EBV-
DNA concentration was significantly higher in NPC patients
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Fig. 3. A. ROC curves of serum EBV-DNA levels and IgG and IgA anti-
bodies to VCA prior to initial therapy. B. ROC curves of serum EBV-DNA
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showed a significant difference between the two groups. The
present findings suggest that RQ-PCR analysis of serum EBV-
DNA could be useful for differential diagnosis between NPC
and NHL.
There has been no previous study regarding the optimal cut-
off point using the ROC curve method for EBV-VCA antibody
titers, or for EBV-DNA quantification. This strict statistical
method gave us an optimal EBV-DNA cut-off point of 6.87
copies/ml prior to therapy, and 60.3 copies/ml at recurrence. In
contrast, the cut-off point for the IgG/VCA titer was 1:640
prior to therapy, and that for the IgA/VCA titer was 1:20. Fur-
thermore, the findings obtained from the ROC analysis clearly
demonstrate that serum EBV-DNA is a more sensitive parame-
ter than the VCA titers. Although comparison of VCA protein
instead of VCA Ig titer with EBV-DNA might be better, we de-
signed this experiment because VCA titers had been considered
to be the “gold standard” tumor markers for NPC.
The cross-sectional study on the level of serum EBV-DNA in
NPC patients with tumor recurrence and in those with complete
remission revealed significantly higher levels of circulating
cell-free EBV-DNA in patients with tumor recurrence than in
patients with complete remission. Occasionally, antibody titers
to VCA in NPC patients continue to show high levels after ini-
tial treatment. IgA/VCA titers decrease gradually to undetect-
able levels within 12 to 30 months even in patients in whom
complete remission was maintained.19–22) Increases in IgA/
VCA titer are a well-known predictor of tumor recurrence;
however, it is also known that IgA/VCA sometimes fails to de-
tect recurrence, probably for the above reason.
ROC analysis was again utilized at recurrence. The VCA ti-
ters were a relatively useful marker prior to initial therapy, but
did not have high diagnostic value at recurrence. In addition,
ROC analysis revealed clear superiority of serum EBV-DNA
quantification over antibodies to VCA in terms of both sensitiv-
ity and specificity.
Our data for sensitivity of both IgG and IgA VCA antibodies
seem lower than those in many other reports, most of which
were from NPC-endemic areas. The results could be due to
geographic differences between high and low NPC incidence
areas. These data suggest that EBV-DNA quantification is a
more valuable diagnostic tool in a low-incidence area for NPC
than in a high-incidence area.
Levels of EBV-DNA in the present study were relatively low
in comparison with the study by Lo et al.7, 8) The present RQ-
PCR system was constructed to examine the BALF5 gene; in
contrast, in their PCR system the BamHI-W region of the EBV
genome or the EBNA1 gene was utilized. Both of these regions
of the genome contain multiple repeat units, but whether these
affect the PCR results is unknown. In addition, we used sub-
cloned plasmid DNA as a positive control, whereas Lo et al.
used an EBV-positive cell line, Namalwa. In addition, they
used plasma, but not serum samples. While we used 200 µl of
serum, they used 800 µl of plasma. The differences in the sys-
tems may have led to the difference in the concentration of
EBV-DNA detected. These factors suggest that EBV-DNA
should be quantitated using a unified PCR system.
In conclusion, detection of cell-free EBV-DNA using RQ-
PCR is suggested to have high fidelity and high diagnostic
value for tumor recurrence in NPC patients. Moreover, the
present results suggest that serum cell-free EBV-DNA quantifi-
cation is a more reliable tumor marker than EBV serological ti-
ters in both high-incidence and low-incidence areas for NPC.
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Table 2.
A. Results of ROC curve analysis prior to initial therapy and at recurrence
Assays % of area under ROC curve Standard error 95% CI Determined cut-off Sensitivity Specificity
Prior to therapy
EBV-DNA quantification 90.71) 0.029 0.849–0.964 6.87 0.855 0.885
IgG/VCA 77.71) 0.044 0.690–0.864 1:640 0.590 0.897
IgA/VCA 77.21) 0.044 0.687–0.858 1:20 0.597 0.897
At recurrence
EBV-DNA quantification 93.51) 0.045 0.846–1.023 60.3 0.909 0.926
IgG/VCA 62.02) 0.099 0.426–0.813 ND ND ND
IgA/VCA 60.92) 0.87 0.437–0.780 ND ND ND
B. Difference under the ROC curve for each assay






Z 2.66 2.57 0.12
P value 0.008∗ 0.011∗ 0.907
At recurrence
Z 2.90 3.32 0.15
P value 0.004∗ <0.001∗ 0.933
IgG/VCA: EBV-specific IgG antibody to viral capsid antigen. IgA/VCA: EBV-specific IgA antibody to viral capsid antigen. ROC curve: receiver-oper-
ating-characteristic curve. CI: confidence intervals.
1) The areas under the ROC curves were significantly larger than the area expected by chance alone.
2) The area under the ROC curve was not significantly larger than the area expected by chance alone.
ND: For IgG/VCA titer and IgA/VCA titers at recurrence, no cut-off point could be determined; those assays did not give efficient diagnostic val-
ues. 
Z: critical ratio of normal distribution. ∗ Statistically significant (P<0.05).512 Kondo et al.
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